azd0284
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 9, 2016 (NCT02976831)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Nuclear receptor ROR-gammaINVERSE AGONIST
RORC inverse agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd0284
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03310320 | Phase 1 | Nov 29, 2017 | AstraZeneca |
| NCT03029741 | Phase 1 | Feb 21, 2017 | AstraZeneca, Quotient |
| NCT02976831 | Phase 1 | Dec 9, 2016 | AstraZeneca, Parexel |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 1 | 2016 |
| Parexel | For profit | 1 | 0 | 1 | 2016 |
| Quotient | For profit | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1